|
Re: BETonMACE baseline data
|
3
|
Resverlogix Corp.
|
Nov 05, 2018 03:19PM
|
|
Final Checklist for Management
|
3
|
Resverlogix Corp.
|
Jul 28, 2016 05:18PM
|
|
Re: Apabetalone MOA diagram
|
3
|
Resverlogix Corp.
|
Sep 28, 2019 10:18AM
|
|
Re: ...FYI... just saying...
|
3
|
Resverlogix Corp.
|
May 10, 2018 10:53AM
|
|
Re: EAS tweet
|
3
|
Resverlogix Corp.
|
Feb 25, 2019 12:13PM
|
|
ERA-EDTA 2019 June 13-16
|
3
|
Resverlogix Corp.
|
Jun 11, 2019 07:28PM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
3
|
Resverlogix Corp.
|
Dec 07, 2017 03:14PM
|
|
Re: Zenith AGM webcast 9/12/2018
|
3
|
Zenith Epigenetics
|
Sep 12, 2018 05:04PM
|
|
Re: Positives & negatives
|
3
|
Resverlogix Corp.
|
Sep 15, 2015 10:29AM
|
|
Stonegate Capital Partners Research Report 3/19/2018
|
3
|
Resverlogix Corp.
|
Mar 19, 2018 04:51PM
|
|
Re: H1 2020 Potential Events
|
3
|
Resverlogix Corp.
|
Mar 01, 2020 03:00PM
|
|
Re: AND, APABETALONE REDUCES CONGESTIVE HEART FAILURE INCIDENCE
|
3
|
Resverlogix Corp.
|
Jun 05, 2020 07:37PM
|
|
Re: We need news on the status of the Third Eye loan....
|
3
|
Resverlogix Corp.
|
Jan 31, 2019 06:30PM
|
|
Re: BETonMACE and Aminotransferases
|
3
|
Resverlogix Corp.
|
Aug 14, 2019 08:49AM
|
|
Resverlogix Announces $15.1 Million of Private Placements
|
3
|
Resverlogix Corp.
|
Apr 01, 2019 11:10AM
|
|
Re: Reply from Sarah
|
3
|
Zenith Epigenetics
|
Dec 12, 2015 09:15AM
|
|
Re: National Kidney Foundation -Abstract: BOM
|
3
|
Resverlogix Corp.
|
Mar 30, 2020 09:51PM
|
|
Re: Apabetalone, a drug that reduces MACE in CKD patients
|
3
|
Resverlogix Corp.
|
Jun 05, 2020 07:41PM
|
|
Re: Trials don't always work out...
|
3
|
Resverlogix Corp.
|
Mar 02, 2016 08:13PM
|
|
Re: To those still complaining about flagging violations and removing posts.....
|
3
|
Resverlogix Corp.
|
Jun 23, 2016 11:23PM
|
